Aurobindo Pharma, a Rs 1475-crore Hyderabad based pharma giant, received USFDA approval for Didanosine (Chewable) Tablets of strengths 100mg, 150mg and 200mg. This is the first generic version approval of Didanosine chewable in the world. Didanosine is a NRTT class of drugs, and a key component of the ARV regimens in various part of the world. This molecule enjoys approximately $100 million of market share.
This product will now be available for consideration for purchase under the PEPFAR. Aurobindo manufactures both API and formulation for this generic. With this approval, the ARV product portfolio of Aurobindo has increased to 17.
Didanosine helps prevent AIDS virus from reproducing. It is used in combination with other antiretroviral agents for the treatment of HIV-1 indication. Didanosine is the version of VIDEX an anti-HIV medication manufactured by Bristol Myers Squibb.